Literature DB >> 7603514

Mitochondrial diabetes mellitus--glucose-induced signaling defects and beta-cell loss.

Y Oka1, H Katagiri, H Ishihara, T Asano, M Kikuchi, T Kobayashi.   

Abstract

Japanese diabetic patients whose mothers were also diabetic were screened, using peripheral leukocytes, for an A to G transition at nucleotide pair 3243 of the mitochondrial gene, a tRNA(Leu)(UUR) mutation. This mutation was identified in four pedigrees from among 300 unrelated patients. Diabetes mellitus cosegretated with the mutation, except in 1 young subject, and was maternally inherited. Long-term follow-up revealed that the underlying disorder in affected members is a progressive impairment of insulin secretion. In accord with this finding, this mutation was found to be highly prevalent in a subset of diabetes mellitus called slowly progressive IDDM; the mutation was identified in 3 of 27 Japanese patients enrolled in the prospective study of islet cell antibody (ICA)-positive, initially non-insulin-dependent diabetic patients, who are very likely to become insulin dependent in several years. The histologic characteristics of slowly progressive IDDM include loss, though incomplete, of pancreatic beta-cells. Mitochondrial gene defects in beta-cells could therefore cause glucose-induced signaling defects as well as beta-cell loss, which explains the wide range of diabetic phenotypes, from NIDDM phenotype to IDDM, in patients with this mitochondrial gene mutation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603514     DOI: 10.1002/mus.880181426

Source DB:  PubMed          Journal:  Muscle Nerve Suppl


  1 in total

1.  The Role of Lactate Exercise Test and Fasting Plasma C-Peptide Levels in the Diagnosis of Mitochondrial Diabetes: Analysis of Clinical Characteristics of 12 Patients With Mitochondrial Diabetes in a Single Center With Long-Term Follow-Up.

Authors:  Yuan Zhao; Ying Zhang; Mengya Qi; Fan Ping; Huabing Zhang; Lingling Xu; Wei Li; Yuxiu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-21       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.